Bard Financial Services Inc. Sells 11,795 Shares of Novo Nordisk A/S $NVO

Bard Financial Services Inc. lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 14.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,970 shares of the company’s stock after selling 11,795 shares during the quarter. Bard Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $4,829,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. First Hawaiian Bank lifted its stake in Novo Nordisk A/S by 0.6% in the 1st quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock valued at $1,556,000 after purchasing an additional 142 shares during the last quarter. Anchor Investment Management LLC lifted its stake in shares of Novo Nordisk A/S by 1.1% in the 1st quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock valued at $944,000 after acquiring an additional 150 shares during the last quarter. Xponance Inc. boosted its holdings in shares of Novo Nordisk A/S by 5.0% during the 1st quarter. Xponance Inc. now owns 3,314 shares of the company’s stock valued at $230,000 after acquiring an additional 158 shares in the last quarter. Foster Dykema Cabot & Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 3.8% during the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock valued at $319,000 after acquiring an additional 166 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its position in Novo Nordisk A/S by 3.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company’s stock worth $348,000 after acquiring an additional 173 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on NVO. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 31st. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. TD Cowen dropped their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 19th. UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $81.00.

Novo Nordisk A/S Stock Up 1.2%

Novo Nordisk A/S stock opened at $54.94 on Monday. The company has a market capitalization of $245.31 billion, a PE ratio of 15.09, a PEG ratio of 2.08 and a beta of 0.66. The firm’s fifty day moving average is $57.96 and its 200 day moving average is $66.17. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $138.22.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.